Juergen Steinmeyer
University of Giessen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Juergen Steinmeyer.
Arthritis & Rheumatism | 2013
M.K. Kosinska; Gerhard Liebisch; Guenter Lochnit; Jochen Wilhelm; Heiko Klein; Ulrich Kaesser; Gabriele Lasczkowski; Markus Rickert; Gerd Schmitz; Juergen Steinmeyer
OBJECTIVE Membrane phospholipid species contribute to boundary lubrication that is provided by synovial fluid (SF). Altered levels of lubricants can be associated with increased friction, leading to articular cartilage damage. This study was undertaken to determine whether the composition of phospholipid species is altered in diseases of human knee joints. METHODS The study was performed using SF from unaffected controls and patients with early osteoarthritis (OA), late OA, or rheumatoid arthritis (RA). Lipids were extracted from cell- and vesicle-free SF from 9 control donors postmortem and from 17 patients with early OA, 13 patients with late OA, and 18 patients with RA. Phospholipid species were quantified by electrospray ionization tandem mass spectrometry. RESULTS We conducted lipidomic analysis to provide the first detailed overview of phospholipid species in human SF. We identified 130 lipid species belonging to 8 lipid classes (phosphatidylcholine, lysophosphatidylcholine, phosphatidylethanolamine, plasmalogens, phosphatidylserine, phosphatidylglycerol, sphingomyelin, and ceramide). Compared to SF from controls, SF from patients with early OA and those with late OA had higher levels of most phospholipid species. Moreover, the concentrations of 64 and 27 phospholipids differed between RA and early OA SF and between RA and late OA SF, respectively. Also, the levels of 66 phospholipid species were altered in early OA versus late OA. CONCLUSION Our data indicate disease- and stage-dependent differences in the relative composition and levels of phospholipid species in human SF. Such alterations might affect articular joint lubrication. Because certain phospholipids scavenge reactive oxygen species (ROS) and are pro- or antiinflammatory, any altered phospholipid level might influence ROS-scavenging activity of SF and the inflammatory status of joints. Thus, phospholipids may be associated with the pathogenesis of OA.
PLOS ONE | 2015
M.K. Kosinska; Taryn E. Ludwig; Gerhard Liebisch; Ruiyan Zhang; Hans-Christian Siebert; Jochen Wilhelm; Ulrich Kaesser; R. Dettmeyer; Heiko Klein; Bernd Ishaque; Markus Rickert; Gerd Schmitz; Tannin A. Schmidt; Juergen Steinmeyer
Background Hyaluronic acid (HA), lubricin, and phospholipid species (PLs) contribute independently or together to the boundary lubrication of articular joints that is provided by synovial fluid (SF). Our study is the first reporting quantitative data about the molecular weight (MW) forms of HA, lubricin, and PLs in SF from cohorts of healthy donors, patients with early (eOA)- or late (lOA)-stage osteoarthritis (OA), and patients with active rheumatoid arthritis (RA). Methods We used human SF from unaffected controls, eOA, lOA, and RA. HA and lubricin levels were measured by enzyme-linked immunosorbent assay. PLs was quantified by electrospray ionization tandem mass spectrometry. Fatty acids (FAs) were analyzed by gas chromatography, coupled with mass spectrometry. The MW distribution of HA was determined by agarose gel electrophoresis. Results Compared with control SF, the concentrations of HA and lubricin were lower in OA and RA SF, whereas those of PLs were higher in OA and RA SF. Moreover, the MW distribution of HA shifted toward the lower ranges in OA and RA SF. We noted distinct alterations between cohorts in the relative distribution of PLs and the degree of FA saturation and chain lengths of FAs. Conclusions The levels, composition, and MW distribution of all currently known lubricants in SF—HA, lubricin, PLs—vary with joint disease and stage of OA. Our study is the first delivering a comprehensive view about all joint lubricants during health and widespread joint diseases. Thus, we provide the framework to develop new optimal compounded lubricants to reduce joint destruction.
Frontiers in Bioscience | 2013
Mona Dvir-Ginzberg; Juergen Steinmeyer
Osteoarthritis (OA) is a degenerative joint disease particularly affecting the elderly population. Although several genetic features have been characterized as risk factors for OA susceptibility, a growing body of evidence indicates that epigenetic effectors may also modulate gene expression and thus contribute to OA pathology. One such epigenetic regulator of particular relevance to OA is Silent Information Regulator 2 type 1 (SirT1) which has been linked to aging and caloric intake, Consistently, SirT1 has been also connected with various age-associated diseases such as diabetes type II, Alzheimers and osteoporosis. Recent reports show that OA is linked to changes in SirT1 activity or levels within cartilage. In human chondrocytes, SirT1 plays a role in cartilage extracellular matrix (ECM) synthesis and promotes cell survival, even under proinflammatory stress. It appears that SirT1 fine tunes many cellular biochemical processes through its capacity to interact and modify various histone and non-histone proteins. Taken together these investigations demonstrate that SirT1 is involved in cartilage biology and could potentially serve as novel drug target in treating OA even at its premature stages, thereby possibly reversing mechanical-stress induced cartilage degeneration.
PLOS ONE | 2014
M.K. Kosinska; Gerhard Liebisch; Guenter Lochnit; Jochen Wilhelm; Heiko Klein; Ulrich Kaesser; Gabriele Lasczkowski; Markus Rickert; Gerd Schmitz; Juergen Steinmeyer
Articular synovial fluid (SF) is a complex mixture of components that regulate nutrition, communication, shock absorption, and lubrication. Alterations in its composition can be pathogenic. This lipidomic investigation aims to quantify the composition of sphingolipids (sphingomyelins, ceramides, and hexosyl- and dihexosylceramides) and minor glycerophospholipid species, including (lyso)phosphatidic acid, (lyso)phosphatidylglycerol, and bis(monoacylglycero)phosphate species, in the SF of knee joints from unaffected controls and from patients with early (eOA) and late (lOA) stages of osteoarthritis (OA), and rheumatoid arthritis (RA). SF without cells and cellular debris from 9 postmortem donors (control), 18 RA, 17 eOA, and 13 lOA patients were extracted to measure lipid species using electrospray ionization tandem mass spectrometry - directly or coupled with hydrophilic interaction liquid chromatography. We provide a novel, detailed overview of sphingolipid and minor glycerophospholipid species in human SF. A total of 41, 48, and 50 lipid species were significantly increased in eOA, lOA, and RA SF, respectively when compared with normal SF. The level of 21 lipid species differed in eOA SF versus SF from lOA, an observation that can be used to develop biomarkers. Sphingolipids can alter synovial inflammation and the repair responses of damaged joints. Thus, our lipidomic study provides the foundation for studying the biosynthesis and function of lipid species in health and most prevalent joint diseases.
Arthritis Research & Therapy | 2015
Louisa Ben-Aderet; Emmanuelle Merquiol; Duha Fahham; Ashok Kumar; Eli Reich; Yael Ben-Nun; Leonid Kandel; Amir Haze; Meir Liebergall; M.K. Kosinska; Juergen Steinmeyer; Boris Turk; Galia Blum; Mona Dvir-Ginzberg
IntroductionLysosomal cathepsins have been reported to contribute to Osteoarthritis (OA) pathophysiology due to their increase in pro-inflammatory conditions. Given the causal role of cathepsins in OA, monitoring their specific activity could provide means for assessing OA severity. To this end, we herein sought to assess a cathepsin activity-based probe (ABP), GB123, in vitro and in vivo.MethodsProtein levels and activity of cathepsins B and S were monitored by immunoblot analysis and GB123 labeling in cultured primary chondrocytes and conditioned media, following stimuli with tumor necrosis factor alpha (TNFα) and/or Interleukin 1 beta (IL-1β). Similarly, cathepsin activity was examined in sections of intact cartilage (IC) and degraded cartilage (DC) regions of OA. Finally, synovial fluid (SF) and serum from donors with no signs of diseases, early OA, late OA and rheumatoid arthritis (RA) patients were analyzed with GB123 to detect distinct activity levels of cathepsin B and S.ResultsCathepsin activity in cell lysates, conditioned media explants and DC sections showed enhanced enzymatic activity of cathepsins B and S. Further histological analysis revealed that cathepsin activity was found higher in superficial zones of DC than in IC. Examining serum and SF revealed that cathepsin B is significantly elevated with OA severity in serum and SF, yet levels of cathepsin S are more correlated with synovitis and RA.ConclusionsBased on our data, cathepsin activity monitored by ABPs correlated well with OA severity and joint inflammation, directing towards a novel etiological target for OA, which possesses significant translational potential in developing means for non-invasive detection of early signs of OA.
Frontiers in Bioscience | 2004
Juergen Steinmeyer
Cytokines and their broad spectrum of effects have been investigated since the 1980s. The already existing preliminary scientific results have been highly suggestive of the idea that cytokines play an essential role in the pathogenesis of OA. Nevertheless, the extent to which cytokines participate in the origin of OA, or are taken as a consequence of the OA process, remain unanswered questions. Unlike the case with rheumatoid arthritis, studies on the application of anti-cytokine medications with OA remain in their infancy. At the present time no clinical studies relating to OA have confirmed that anti-cytokine medications are antiphlogistically effective and/or prevent the origin of morphologically recognizable cartilage defects or at least decelerate the increasing destruction of joint cartilage. As with every other therapeutic approach the risk-benefit scenario is decisive for deciding on the current application of anti cytokine medications for rheumatoid arthritis as well as their potential future use against OA. Considering the long-term consequences of an anti-cytokine based therapy, our poor state of knowledge should be seen in a very critical light, since the discussed approach represents an immunesuppressive therapy that entails consequences with regard to defence against infections and tumour suppression. Also, little is currently known about the interplay between pro- and anti-inflammatory cytokines and growth factors in OA; the resulting specific and fundamental therapeutic possibilities for performing a structure-modifying basic therapy in OA are worthy of further study on the part of academic and industrial institutions.
International Journal of Molecular Sciences | 2017
Saskia Schadow; Viktor Simons; Guenter Lochnit; Jens Kordelle; Zuzana Gazova; Hans-Christian Siebert; Juergen Steinmeyer
The most frequent disease of the locomotor system is osteoarthritis (OA), which, as a chronic joint disease, might benefit more from nutrition than acute illnesses. Collagen hydrolysates (CHs) are peptidic mixtures that are often used as nutraceuticals for OA. Three CHs were characterized biochemically and pharmacologically. Our biophysical (MALDI-TOF-MS, NMR, AFM) and fluorescence assays revealed marked differences between CHs of fish (Peptan® F 5000, Peptan® F 2000) and porcine (Mobiforte®) origin with respect to the total number of peptides and common peptides between them. Using a novel dual radiolabeling procedure, no CH modulated collagen biosynthesis in human knee cartilage explants. Peptan® F 2000 enhanced the activities of the aggrecanase ADMATS4 and ADMATS5 in vitro without loss of proteoglycan from cartilage explants; the opposite effect was observed with Mobiforte®. Interleukin (IL)-6, matrix metalloproteinase (MMP)-1, -3 and -13 levels were elevated in explants that were treated with Mobiforte® and Peptan® F 5000, but not with Peptan® F 2000. In conclusion, the heterogeneous peptide composition and disparate pharmacological effects between CHs suggest that the effect of a CH preparation cannot be extrapolated to other formulations. Thus, the declaration of a CH as a safe and effective nutraceutical requires a thorough examination of its pleiotropic effects.
Aging Cell | 2016
Michal Bar Oz; Ashok Kumar; Jinan Elayyan; Eli Reich; Milana Binyamin; Leonid Kandel; Meir Liebergall; Juergen Steinmeyer; Véronique Lefebvre; Mona Dvir-Ginzberg
Changes in the content of aggrecan, an essential proteoglycan of articular cartilage, have been implicated in the pathophysiology of osteoarthritis (OA), a prevalent age‐related, degenerative joint disease. Here, we examined the effect of SOX9 acetylation on ACAN transactivation in the context of osteoarthritis. Primary chondrocytes freshly isolated from degenerated OA cartilage displayed lower levels of ACAN mRNA and higher levels of acetylated SOX9 compared with cells from intact regions of OA cartilage. Degenerated OA cartilage presented chondrocyte clusters bearing diffused immunostaining for SOX9 compared with intact cartilage regions. Primary human chondrocytes freshly isolated from OA knee joints were cultured in monolayer or in three‐dimensional alginate microbeads (3D). SOX9 was hypo‐acetylated in 3D cultures and displayed enhanced binding to a −10 kb ACAN enhancer, a result consistent with higher ACAN mRNA levels than in monolayer cultures. It also co‐immunoprecipitated with SIRT1, a major deacetylase responsible for SOX9 deacetylation. Finally, immunofluorescence assays revealed increased nuclear localization of SOX9 in primary chondrocytes treated with the NAD SIRT1 cofactor, than in cells treated with a SIRT1 inhibitor. Inhibition of importin β by importazole maintained SOX9 in the cytoplasm, even in the presence of NAD. Based on these data, we conclude that deacetylation promotes SOX9 nuclear translocation and hence its ability to activate ACAN.
Scientific Reports | 2017
Katarzyna D. Sluzalska; Gerhard Liebisch; Jochen Wilhelm; Bernd Ishaque; Holger Hackstein; Gerd Schmitz; Markus Rickert; Juergen Steinmeyer
Elevated levels of growth factors and phospholipids (PLs) have been found in osteoarthritic synovial fluid (SF), although the metabolic regulation of PLs is currently unknown. This study aimed to determine the effects of growth factors on the biosynthesis of PLs by fibroblast-like synoviocytes (FLS) obtained from human osteoarthritic knee joints. Electrospray ionization tandem mass spectrometry was applied to analyse the newly synthesized PLs. In the presence of stable isotope-labelled PL precursors, cultured FLS were treated with either transforming growth factor-β1 (TGF-β1), bone morphogenetic protein (BMP)-2, BMP-4, BMP-7 or insulin-like growth factor-1 (IGF-1) alone or in combination with specific inhibitors of cell signalling pathways. TGF-β1 and IGF-1 markedly stimulated the biosynthesis of phosphatidylcholine (PC) before sphingomyelin (SM) and lysophosphatidylcholine (LPC) species were stimulated. BMPs elaborated less pronounced effects. The BMPs tested have different potentials to induce the biosynthesis of phosphatidylethanolamine (PE) and PE-based plasmalogens. Our study shows for the first time that TGF-β1 and IGF-1 substantially regulate the biosynthesis of PC, SM and LPC in human FLS. The functional consequences of elevated levels of PLs require additional study. The BMPs tested may be joint protective in that they upregulate PE-based plasmalogens that function as endogenous antioxidants against reactive oxygen species.
Osteoarthritis and Cartilage | 2005
B. Ackermann; Juergen Steinmeyer